{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T01:15:43Z","timestamp":1778289343005,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.beha.2012.04.001","type":"journal-article","created":{"date-parts":[[2012,4,30]],"date-time":"2012-04-30T22:53:26Z","timestamp":1335826406000},"page":"191-200","source":"Crossref","is-referenced-by-count":4,"title":["Novel agents in mantle cell lymphoma"],"prefix":"10.1016","volume":"25","author":[{"given":"Marcus S.","family":"Noel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M.","family":"Barr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.beha.2012.04.001_bib1","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/annonc\/mdn045","article-title":"Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies","volume":"19","author":"Martin","year":"2008","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology\/ESMO. [Research Support, Non-U.S. Gov't]"},{"issue":"16","key":"10.1016\/j.beha.2012.04.001_bib2","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1182\/blood-2011-06-338855","article-title":"B-cell receptor signaling in chronic lymphocytic leukemia","volume":"118","author":"Stevenson","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2012.04.001_bib3","first-page":"26","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era","volume":"117","author":"Perez-Galan","year":"2011","journal-title":"Blood. [Research Support, N.I.H., Intramural Review]"},{"issue":"2","key":"10.1016\/j.beha.2012.04.001_bib4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s13402-011-0019-7","article-title":"Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling","volume":"34","author":"Pighi","year":"2011","journal-title":"Cell Oncology (Dordr). [Research Support, Non-U.S. Gov't]"},{"issue":"3","key":"10.1016\/j.beha.2012.04.001_bib5","first-page":"303","article-title":"Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma","volume":"132","author":"Rinaldi","year":"2006","journal-title":"British Journal of Haematology. [Research Support, Non-U.S. Gov't]"},{"issue":"13","key":"10.1016\/j.beha.2012.04.001_bib6","first-page":"2578","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood. [Clinical Trial, Phase I Clinical Trial, Phase II Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]"},{"issue":"29","key":"10.1016\/j.beha.2012.04.001_bib7","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"23","key":"10.1016\/j.beha.2012.04.001_bib8","first-page":"6287","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","volume":"117","author":"Herman","year":"2011","journal-title":"Blood. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]"},{"issue":"21","key":"10.1016\/j.beha.2012.04.001_bib9","first-page":"964","article-title":"The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed\/refractory B-cell malignancies: results from a phase I study","volume":"116","author":"Fowler","year":"2010","journal-title":"ASH Annual Meeting Abstracts 2010"},{"issue":"31","key":"10.1016\/j.beha.2012.04.001_bib10","first-page":"19236","article-title":"p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes","volume":"272","author":"Chantry","year":"1997","journal-title":"The Journal of Biological Chemistry. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]"},{"issue":"2","key":"10.1016\/j.beha.2012.04.001_bib11","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.beha.2012.04.001_bib12","first-page":"3603","article-title":"The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood. [Research Support, Non-U.S. Gov't]"},{"issue":"21","key":"10.1016\/j.beha.2012.04.001_bib13","first-page":"1777","article-title":"Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"116","author":"Kahl","year":"2010","journal-title":"ASH Annual Meeting Abstracts 2010"},{"issue":"21","key":"10.1016\/j.beha.2012.04.001_bib14","first-page":"2832","article-title":"A phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, in combination with rituximab and\/or bendamustine in patients with relapsed or refractory B-cell malignancies","volume":"116","author":"Flinn","year":"2010","journal-title":"ASH Annual Meeting Abstracts 2010"},{"issue":"5","key":"10.1016\/j.beha.2012.04.001_bib15","first-page":"1668","article-title":"Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma","volume":"108","author":"Rudelius","year":"2006","journal-title":"Blood. [Research Support, N.I.H., Intramural]"},{"issue":"7","key":"10.1016\/j.beha.2012.04.001_bib16","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1158\/1535-7163.MCT-09-1012","article-title":"MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in\u00a0vitro and in\u00a0vivo","volume":"9","author":"Hirai","year":"2010","journal-title":"Molecular Cancer Therapeutics. [Research Support, Non-U.S. Gov't]"},{"issue":"5","key":"10.1016\/j.beha.2012.04.001_bib17","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1182\/blood-2010-06-255067","article-title":"Novel therapeutic agents for B-cell lymphoma: developing rational combinations","volume":"117","author":"Reeder","year":"2011","journal-title":"Blood. [Review]"},{"issue":"2","key":"10.1016\/j.beha.2012.04.001_bib18","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/annonc\/mdm463","article-title":"A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma","volume":"19","author":"Morschhauser","year":"2008","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology\/ESMO. [Clinical Trial, Phase II Research Support, Non-U.S. Gov't]"},{"issue":"7","key":"10.1016\/j.beha.2012.04.001_bib19","first-page":"2026","article-title":"Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in\u00a0vitro and in\u00a0vivo: therapeutic implications","volume":"9","author":"Pham","year":"2010","journal-title":"Molecular Cancer Therapeutics. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]"},{"issue":"11","key":"10.1016\/j.beha.2012.04.001_bib20","first-page":"1865","article-title":"Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma","volume":"95","author":"Baran-Marszak","year":"2010","journal-title":"Haematologica. [Clinical Trial Multicenter Study Research Support, Non-U.S. Gov't]"},{"issue":"21","key":"10.1016\/j.beha.2012.04.001_bib21","first-page":"2731","article-title":"The small molecule JAK1\/JAK2 inhibitor INCB16562 shows single agent activity and strongly synergizes with Bcl-2 inhibitors in lymphoma","volume":"118","author":"Derenzini","year":"2011","journal-title":"ASH Annual Meeting Abstracts 2011"},{"issue":"18","key":"10.1016\/j.beha.2012.04.001_bib22","doi-asserted-by":"crossref","first-page":"5973","DOI":"10.1158\/1078-0432.CCR-11-0955","article-title":"ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high\/Mcl-1low profile and synergizes with other antineoplastic agents","volume":"17","author":"Touzeau","year":"2011","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. [Research Support, Non-U.S. Gov't]"},{"issue":"10","key":"10.1016\/j.beha.2012.04.001_bib23","first-page":"4441","article-title":"The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak","volume":"109","author":"Perez-Galan","year":"2007","journal-title":"Blood. [Evaluation Studies Research Support, Non-U.S. Gov't]"},{"issue":"30","key":"10.1016\/j.beha.2012.04.001_bib24","first-page":"12461","article-title":"A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma","volume":"108","author":"Beltran","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]"},{"issue":"9","key":"10.1016\/j.beha.2012.04.001_bib25","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Research"},{"issue":"21","key":"10.1016\/j.beha.2012.04.001_bib26","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1200\/JCO.2010.27.9836","article-title":"Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies","volume":"28","author":"Cheson","year":"2010","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. [Review]"},{"issue":"10","key":"10.1016\/j.beha.2012.04.001_bib27","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1345\/aph.1P780","article-title":"Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia","volume":"45","author":"Nightingale","year":"2011","journal-title":"The Annals of Pharmacotherapy"},{"issue":"12","key":"10.1016\/j.beha.2012.04.001_bib28","first-page":"5486","article-title":"First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1\/2 trial","volume":"111","author":"Hagenbeek","year":"2008","journal-title":"Blood. [Clinical Trial, Phase I Clinical Trial, Phase II Multicenter Study Research Support, Non-U.S. Gov't]"},{"issue":"26","key":"10.1016\/j.beha.2012.04.001_bib29","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1200\/JCO.2008.21.3017","article-title":"Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma","volume":"27","author":"Advani","year":"2009","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. [Clinical Trial, Phase I Multicenter Study]"},{"issue":"17","key":"10.1016\/j.beha.2012.04.001_bib30","first-page":"4530","article-title":"Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in\u00a0vitro and in\u00a0vivo activity in mantle cell lymphoma","volume":"117","author":"Alinari","year":"2011","journal-title":"Blood. [In\u00a0Vitro Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]"},{"issue":"32","key":"10.1016\/j.beha.2012.04.001_bib31","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1200\/JCO.2009.22.1291","article-title":"Histone deacetylase inhibitors in cancer therapy","volume":"27","author":"Lane","year":"2009","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. [Review]"},{"issue":"12","key":"10.1016\/j.beha.2012.04.001_bib32","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1158\/1078-0432.CCR-10-3412","article-title":"Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters","volume":"17","author":"Xargay-Torrent","year":"2011","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. [Research Support, Non-U.S. Gov't]"},{"issue":"9","key":"10.1016\/j.beha.2012.04.001_bib33","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.2010.32.1398","article-title":"Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"29","author":"Kirschbaum","year":"2011","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. [Clinical Trial, Phase II Research Support, N.I.H., Extramural]"},{"issue":"4","key":"10.1016\/j.beha.2012.04.001_bib34","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.exphem.2007.12.008","article-title":"Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma","volume":"36","author":"Yazbeck","year":"2008","journal-title":"Experimental Hematology"},{"issue":"7","key":"10.1016\/j.beha.2012.04.001_bib35","first-page":"881","article-title":"Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma","volume":"81","author":"Qi","year":"2011","journal-title":"Biochemical Pharmacology. [Research Support, N.I.H., Extramural"},{"key":"10.1016\/j.beha.2012.04.001_bib36","doi-asserted-by":"crossref","unstructured":"Session 14: signalling pathways in lymphoma. Ann Oncol. 2011 June 1, 2011; 22(Suppl. 4): iv135\u2013iv137.","DOI":"10.1093\/annonc\/mdr211"},{"issue":"11","key":"10.1016\/j.beha.2012.04.001_bib37","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.leukres.2006.03.004","article-title":"Induction of apoptosis and down regulation of cell cycle proteins in mantle cell lymphoma by flavopiridol treatment","volume":"30","author":"Venkataraman","year":"2006","journal-title":"Leukemia Research"},{"issue":"3","key":"10.1016\/j.beha.2012.04.001_bib38","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1200\/JCO.2009.24.1570","article-title":"Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders","volume":"28","author":"Lin","year":"2010","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. [Clinical Trial, Phase I Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]"},{"issue":"16","key":"10.1016\/j.beha.2012.04.001_bib39","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1200\/JCO.2008.19.7681","article-title":"Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies","volume":"27","author":"Kummar","year":"2009","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. [Clinical Trial Research Support, N.I.H., Extramural]"},{"issue":"22","key":"10.1016\/j.beha.2012.04.001_bib40","first-page":"4578","article-title":"The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in\u00a0vitro and in\u00a0vivo","volume":"116","author":"Weston","year":"2010","journal-title":"Blood. [Research Support, Non-U.S. Gov't]"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169261200028X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169261200028X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T03:36:57Z","timestamp":1561693017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152169261200028X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S152169261200028X"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2012.04.001","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}